CNXU · Conexeu Sciences Inc. Common Stock
View on chartInsiders & Stakes
| Purcell Lynn Sebastian Director | ▼ Sell | Other | 2,951,848 Shares held | 9/4/2026 | View profile |
| Wright Michael G. 10% Owner | ▲ Buy | Option Exercise | 2,148,048 Shares held | 6/18/2026 | View profile |
| Bogart David Robert Chief Commercial Officer | ▲ Buy | Option Exercise | 1,812,500 Shares held | 9/25/2026 | View profile |
| Sharpe Jeffrey Nathan Director | ▲ Buy | Option Exercise | 1,500,000 Shares held | 9/14/2026 | View profile |
| OnePointTwo Capital Ventures LLC 10% Owner | ▲ Buy | Open Market | 1,047,500 Shares held | 5/12/2026 | View profile |
| Lorenc Zbigniew Paul Director | ▲ Buy | Grant | 433,323 Shares held | 5/14/2026 | View profile |
Transaction History
| Bogart David Robert | ▲ Buy | Option Exercise | 750,000 | $750 | 9/25/2026 |
| Sharpe Jeffrey Nathan | ▲ Buy | Option Exercise | 500,000 | $500 | 9/14/2026 |
| Purcell Lynn Sebastian | ▼ Sell | Other | 217,608 | $500K | 9/4/2026 |
| Purcell Lynn Sebastian | ▲ Buy | Open Market | 202,500 | $162K | 6/18/2026 |
| Wright Michael G. | ▲ Buy | Option Exercise | 250,000 | $250 | 6/18/2026 |
| Wright Michael G. | ▲ Buy | Option Exercise | 400,000 | $400 | 5/26/2026 |
| Sharpe Jeffrey Nathan | ▲ Buy | Option Exercise | 500,000 | $500 | 5/22/2026 |
| Lorenc Zbigniew Paul | ▲ Buy | Grant | 11,175 | $0 | 5/14/2026 |
| OnePointTwo Capital Ventures LLC | ▲ Buy | Open Market | 422,500 | $338K | 5/12/2026 |
| Purcell Lynn Sebastian | ▲ Buy | Open Market | 422,500 | $338K | 5/12/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
CNXU Provides Update on FDA 510(k) Program for Wound Care Device
Conexeu Sciences released an update describing its regulatory and manufacturing program that supports a planned FDA 510(k) premarket notification for a ten‑minute tissue, lead wound‑care device candidate. The announcement signals progress toward filing the notification and may affect the timeline for potential market entry. The stock is currently near a support level of $9.62 and has an RSI of 31.4, suggesting limited momentum.
CNXU Provides Update on FDA 510(k) Program for Wound Care Device. Conexeu Sciences released an update describing its regulatory and manufacturing program that supports a planned FDA 510(k) premarket notification for a ten‑minute tissue, lead wound‑care device candidate. The announcement signals progress toward filing the notification and may affect the timeline for potential market entry. The stock is currently near a support level of $9.62 and has an RSI of 31.4, suggesting limited momentum.